Risk factors, prevention and treatment of hypertension in pregnancy

Minerva Ginecologica

Volumn 57, Issue 4, 2005, Pages 379-388

  Smith, R A ^a   Baker, P N ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Hypertension; Pregnancy induced hypertension; Pregnancy, Preeclampsia; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; BETAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; HYDRALAZINE; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM SULFATE; METHYLDOPA; NIFEDIPINE;

CHRONIC KIDNEY FAILURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; FLUID BALANCE; GENETICS; HIGH RISK PREGNANCY; HUMAN; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; OBESITY; PERINATAL MORTALITY; PREECLAMPSIA; REVIEW; RISK FACTOR; SCREENING; SOCIOECONOMICS;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; ASPIRIN; CALCIUM CHANNEL BLOCKERS; CALCIUM, DIETARY; CONTROLLED CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; MAGNESIUM SULFATE; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS; SOCIOECONOMIC FACTORS; ULTRASONOGRAPHY, DOPPLER; WATER-ELECTROLYTE BALANCE;

EID: 27144513292     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. James PR, Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart 2004;90:1499-504.
2. Villar J, Say L, Shennan A, Lindheimer M, Duley L, Conde-Agudelo A et al. Methodological and technical issues related to the diagnosis, screening, prevention, and treatment of pre-eclampsia and eclampsia. Int J Gynaecol Obstet 2004;85 Suppl 1:S28-41.
3. Draper ES, Manktelow B, Field DJ, James D. Prediction of survival for preterm births by weight and gestational age: retrospective population based study. BMJ 1999;319:1093-7.
4. Hauth JC, Ewell MG, Levine RJ, Esterlitz JR, Sibai B, Curet LB et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000;95:24-8.
5. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181-92.
6. Barton JR, O'Brien JM, Bergauer NK, Jacques DL, Sibai BM. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol 2001;184:979-83.
7. McCowan LM, Buist RG, North RA, Gamble G. Perinatal morbidity in chronic hypertension. Br J Obstet Gynaecol 1996;103:123-9.
8. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000;355:87-92.
9. Magee LA, Abdullah S. The safety of antihypertensives for treatment of pregnancy hypertension. Expert Opin Drug Saf 2004;3:25-38.
10. Scholz HS, Haas J, Petru E. Do primiparas aged 40 years or older carry an increased obstetric risk? Prev Med 1999;29:263-6.
11. Haelterman E, Qvist R, Barlow P, Alexander S. Social deprivation and poor access to care as risk factors for severe pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2003;111:25-32.
12. Samadi AR, Mayberry RM, Reed JW. Preeclampsia associated with chronic hypertension among African-American and White women. Ethn Dis 2001;11:192-200.
13. Lydakis C, Beevers DG, Beevers M, Lip GY. Obstetric and neonatal outcome following chronic hypertension in pregnancy among different ethnic groups. QJM 1998;91:837-44.
14. Irwin DE, Savitz DA, Hertz-Picciotto I, St Andre KA. The risk of pregnancy-induced hypertension: black and white differences in a military population. Am J Public Health 1994;84:1508-10.
15. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. Br J Obstet Gynaecol 2004;111:200-6.
16. Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. JAMA 1991;266:237-41.
17. Saftlas AF, Levine RJ, Klebanoff MA, Martz KL, Ewell MG, Morris CD et al. Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol 2003;157:1108-14.
18. Salha O, Sharma V, Dada T, Nugent D, Rutherford AJ, Tomlinson AJ et al. The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Hum Reprod 1999;14:2268-73.
19. Mostello D, Catlin TK, Roman L, Holcomb WL Jr, Leet T. Preeclampsia in the parous woman: who is at risk? Am J Obstet Gynecol 2002;187:425-9.
20. Sibai BM, Hauth J, Caritis S, Lindheimer MD, MacPherson C, Klebanoff M et al. Hypertensive disorders in twin versus singleton gestations. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 2000;182:938-42.
21. Savvidou MD, Karanastasi E, Skentou C, Geerts L, Nicolaides KH. Twin chorionicity and pre-eclampsia. Ultrasound Obstet Gynecol 2001;18:228-31.
22. Dunne F, Brydon P, Smith K, Gee H. Pregnancy in women with Type 2 diabetes: 12 years outcome data 1990-2002. Diabet Med 2003;20:734-8.
23. Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nation-wide prospective study in the Netherlands. BMJ 2004;328:915.
24. Garner PR, D'Alton ME, Dudley DK, Huard P, Hardie M. Preeclampsia in diabetic pregnancies. Am J Obstet Gynecol 1990;163:505-8.
25. Bryson CL, Ioannou GN, Rulyak SJ, Critchlow C. Association between gestational diabetes and pregnancy-induced hypertension. Am J Epidemiol 2003;158:1148-53.
26. Fink JC, Schwartz SM, Benedetti TJ, Stehman-Breen CO. Increased risk of adverse maternal and infant outcomes among women with renal disease. Paediatr Perinat Epidemiol 1998;12:277-87.
27. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1258-65.
28. Weiss JL, Malone FD, Emig D, Ball RH, Nyberg DA, Comstock CH et al. Obesity, obstetric complications and cesarean delivery rate-a population-based screening study. Am J Obstet Gynecol 2004;190:1091-7.
29. Yu CK, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. Ultrasound Obstet Gynecol 2003;22:233-9.
30. Papageorghiou AT, Yu CK, Nicolaides KH. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004;18:383-96.
31. Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:441-9.
32. Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:583-6.
33. Vainio M, Riutta A, Koivisto AM, Maenpaa J. Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. Acta Obstet Gynecol Scand 2004;83:1119-23.
34. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994;343:619-29.
35. Hauth JC, Goldenberg RL, Parker CR Jr, Philips JB 3rd, Copper RL, DuBard MB et al. Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol 1993;168:1083-91; discussion 1091-3.
36. Vainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. Br J Obstet Gynaecol 2002;109:161-7.
37. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 2001;322:329-33.
38. Roberts JM, Hubel CA. Oxidative stress in preeclampsia. Am J Obstet Gynecol 2004;190:1177-8.
39. Roggensack AM, Zhang Y, Davidge ST. Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension 1999;33:83-9.
40. Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 1999;354:810-6.
41. Olsen SF, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. Br J Obstet Gynaecol 2000;107:382-95.
42. Levine RJ, Esterlitz JR, Raymond EG, DerSimonian R, Hauth JC, Ben Curet L et al. Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods. Control Clin Trials 1996;17:442-69.
43. Levine RJ, Hauth JC, Curet LB, Sibai BM, Catalano PM, Morris CD et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997;337:69-76.
44. Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2002:CD001059.
45. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2001:CD002252.
46. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2000:CD000065.
47. Antenatal Corticosteroids to prevent Respiratory Distress Syndrome. London: Royal College of Obstetricians and Gynaecologists; February 2004.
48. Haddad B, Deis S, Goffinet F, Paniel BJ, Cabrol D, Siba BM. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2004;190:1590-5; discussion 1595-7.
49. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994;171:818-22.
50. Chammas MF, Nguyen TM, Li MA, Nuwayhid BS, Castro LC. Expectant management of severe preterm preeclampsia: is intrauterine growth restriction an indication for immediate delivery? Am J Obstet Gynecol 2000;183:853-8.
51. Witlin AG, Saade GR, Mattar F, Sibai BM. Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2000;182:607-11.
52. Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev 2003:CD000127.
53. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:1877-90.
54. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982;1:647-9.
55. el-Qarmalawi AM, Morsy AH, al-Fadly A, Obeid A, Hashem M. Labetalol vs methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet 1995;49:125-30.
56. Montan S. Drugs used in hypertensive diseases in pregnancy. Curr Opin Obstet Gynecol 2004;16:111-5.
57. From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy-United States, Canada, and Israel, 1987-1995. JAMA 1997;277:1193-4.
58. Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 2003;12:633-46.
59. Confidential Enquiry into Maternal and Child Health. Why Mothers Die 2000-2002. London: RCOG Press; 2004.
60. Baldwin KJ, Leighton NA, Kilby MD, Wyldes M, Churchill D, Johanson RB. The West Midlands "Severe Hypertensive Illness in Pregnancy" (SHIP) audit. Hypertens Pregnancy 2001;20:257-68.